6:17 PM
 | 
Sep 28, 2012
 |  BC Extra  |  Company News

Novo's insulin degludec approved in Japan

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Tresiba insulin degludec to treat Type I and Type II diabetes. Novo Nordisk expects to launch Tresiba in Japan when pricing...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >